<DOC>
	<DOC>NCT00190424</DOC>
	<brief_summary>The purpose of this study is to determine whether the immunostimulating agent CpG-ODN is effective in the treatment of glioblastoma</brief_summary>
	<brief_title>Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>CPG-oligonucleotide</mesh_term>
	<criteria>Glioblastoma Karnofsky Performance Status â‰¥ 60% Severe or uncontrolled systemic disease Active autoimmune disease Uncontrolled epilepsia Platelets &lt; 100 000/mm3 ; or Neutrophils &lt;500 /mm3 ; or lymphocytes &lt;300/ mm3</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>